Abstract
Objective: Distinguishing undifferentiated-type (diffuse-type) from differentiated-type (intestinal-type) cancer is crucial for determining the indication of endoscopic resection for gastric cancer. This study aimed to evaluate on-site diagnostic performance of conventional white-light endoscopy (WLE) and magnifying narrow-band imaging (M-NBI) in determining the subtype of gastric cancer. Design: We conducted a multicenter prospective single-arm trial. Patients who planned to undergo treatment for histologically proven cT1 gastric cancer were recruited from six tertiary care institutions. The primary and key secondary endpoints were diagnostic accuracy and specificity, respectively. The diagnostic algorithm of WLE was based on lesion color. The M-NBI algorithm was based on the microsurface and microvascular patterns. Results: A total of 208 patients were enrolled. After protocol endoscopy, 167 gastric cancers were included in the analysis. The accuracy, sensitivity, specificity, and positive likelihood ratio of WLE for undifferentiated-type cancer were 80% (95% CI 73%-86%), 69% (53%-82%), 84% (77%-90%), and 4.4 (2.8-7.0), respectively. Those of M-NBI were 82% (75%-88%), 53% (38%-68%), 93% (87%-97%), and 7.2 (3.6-14.4), respectively. There was no significant difference in accuracy between WLE and M-NBI (p = 0.755), but specificity was significantly higher with M-NBI than with WLE (p = 0.041). Those of M-NBI combined with WLE were 81% (74%-87%), 38% (24%-54%), 97% (92%-99%), and 11.5 (4.1-32.4), respectively. Conclusion: M-NBI is more specific than WLE in distinguishing undifferentiated-type from differentiated-type gastric cancer and M-NBI combined with WLE is highly reliable (positive likelihood ratio >10). Trial registration number UMIN000032151.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
UMIN000032151
Clinical Protocols
https://www.umin.ac.jp/icdr/index.html
Funding Statement
The Yasuda Medical Foundation
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by the institutional Review Board of Osaka International Cancer Institute, institutional Review Board of Ishikawa Prefectural Central Hospital, institutional Review Board of Fukuoka University Chikushi Hospital, institutional Review Board of Kochi Red Cross Hospital, institutional Review Board of Oita Red Cross Hospital, and institutional Review Board of Juntendo University.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
